Woodline Partners’s Atrium Therapeutics RNA Stock Holding History

Woodline Partners’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28,845	Closed	-$386K	–	1187
2026 Q1	$386K	Buy	+28,845	New	+$405K	﹤0.01%	985

Other funds holding RNA

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Woodline Partners's RNA Position: Q2 2026 in Review

Woodline Partners sold out of Atrium Therapeutics (RNA) in Q2 2026, closing a stake of 28,845 shares — an estimated $386K sold.

Woodline Partners first reported a position in RNA in Q1 2026 and held it in 1 quarter. The position peaked at $386K in Q1 2026. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

Woodline Partners reported no remaining Atrium Therapeutics position as of Q2 2026 after selling out during the quarter.
Woodline Partners sold 28,845 Atrium Therapeutics shares in Q2 2026, an estimated $386K.
Woodline Partners first reported a position in Atrium Therapeutics in Q1 2026 and held it in 1 quarter.
Woodline Partners's Atrium Therapeutics position peaked at $386K in Q1 2026.
155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.